Bridgepoint Development Capital picks up Quotient

BDC intends to capitalise on the 6% annual growth rate forecast for the outsourced drug development market, which is currently valued at $30bn.

Debt
Debt for the deal was provided by HSBC.

Company
Quotient Clinical has developed a platform that integrates formulation development, real-time drug product manufacturing and clinical testing in order to reduce the time and cost of bringing a drug to market.

The business services pharmaceutical companies, with more than 75% of its revenues generated from US or European customers.

The company has two facilities in the UK, one in Nottingham and the other in Edinburgh, and employs 200 people.

People
Mark Egerton is CEO of Quotient Clinical.

Advisers
Equity – EY (Financial due diligence); Travers Smith (Legal); LEK (Commercial due diligence).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Buyouts
• UK / Ireland
• Healthcare
• United Kingdom
• Bridgepoint